Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Medicine

Rutgers New Jersey Medical School Research: Controlling Diabetes with Your Phone Might be Possible Someday

Newark, NJ, November 27, 2017 — Think about this.  You have diabetes, are trying to control your insulin levels and instead of taking a pill or giving yourself an injection, you click an app on your phone that tells your pancreas to bring blood sugar levels back to normal.

Sound improbable?  Not according to Luis Ulloa, an immunologist at Rutgers New Jersey Medical School in a paper published in Trends in Molecular Medicine.

“Our bodies are a lot like rooms in a house,” says Ulloa. “In order to see when you enter a darkened room, you need electricity to turn on the lights. Our body is like that room and has an electrical network that can be used to manipulate and help control how it works.” Continue reading

FDA Announces Comprehensive Regenerative Medicine Policy Framework

Washington, DC, November 20, 2017 — The U.S. Food and Drug Administration (FDA) on November 16 announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

The framework – outlined in a suite of four guidance documents – builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products.

Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, November 11, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a September report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

Seton Hall-Hackensack-Meridian School of Medicine’s Dean Bonita Stanton to Be Honored by Tri-County Scholarship Fund on November 6

Dean Bonita Stanton

Whippany, NJ, October 27, 2017 — Michael Ricciardelli reports that Dr. Bonita Stanton, founding dean of the Seton Hall-Hackensack-Meridian School of Medicine, has been honored by the Tri-County Scholarship Fund.

Dean Stanton’s award will be presented at the Fund’s 36th annual Gala Awards Dinner at the Hanover Marriott in Whippany, celebrating more than three decades of helping financially needy students in Morris, Passaic and Sussex counties on November 6, 2017.

The mission of Tri-County Scholarship Fund is to provide financial support for deserving students to obtain a quality, values-based education in accredited private elementary and secondary schools. Continue reading

Hackensack University Medical Center Foundation Receives Donation from Celgene to Advance Multiple Myeloma Research at John Theurer Cancer Center

Former Roche campus to be new Seton Hall-Hackensack Meridian School of Medicine

Hackensack, NJ, October 20, 2017 — The Hackensack University Medical Center Foundation announced on October 5 that it has received a substantial donation from Celgene Corporation to advance multiple myeloma research and transformational medicine that improve patient outcomes at Hackensack Meridian Health–John Theurer Cancer Center.

Supported by Celgene, a global biopharmaceutical leader in the discovery, development and delivery of treatment for diseases like multiple myeloma (MM), funds will help to establish the Multiple Myeloma Institute (MMI) — a leading-edge research facility at the Seton Hall-Hackensack Meridian School of Medicine scheduled to open in 2018.

Celgene and John Theurer Cancer Center are accomplished leaders in developing novel therapies for patients with multiple myeloma. Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, September 16, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading

Robert and Laura Garrett Gift $2.65 Million to Endow Seton Hall-Hackensack Meridian Med School Dean’s Post

Robert and Laura Garrett

Hackensack, NJ, August 3, 2017 — Anjalee Khemlani reports in NJBIZ that Hackensack Meridian Health co-CEO Robert Garrett and his wife, Laura Garrett, have provided a $2.65 million gift in honor of the new Seton Hall-Hackensack Meridian School of Medicine’s founding dean, Dr. Bonita Stanton.

Dr. Stanton was appointed to the Robert C. and Laura C. Garrett Endowed Chair for the School of Medicine Dean.

“Endowed chairs are among the highest honors conferred in academia, and the $15 million in support of endowments at Hackensack University Medical Center reinforces its role as one of the top-ranked academic medical centers in the country,” the health system said in a statement. Continue reading

U.N. Report: Over Half of People with HIV Having Treatment for First Time

London, July 31, 2017 — The Associated Press’ Maria Cheng reports that that, for the first time in the global AIDS epidemic that has spanned four decades and killed 35 million people, more than half of all those infected with HIV are on drugs to treat the virus, the United Nations said in a report released in Paris on July 20.

AIDS deaths are also now close to half of what they were in 2005, according to the U.N. AIDS agency, although those figures are based on estimates and not actual counts from countries.

Experts applauded the progress, but questioned if the billions spent in the past two decades should have brought more impressive results.  Continue reading

Opinion: NJAMHAA Mary Abrams Urges NJ’s Members of Congress to Reject GOP Interference with Medicare Part D

New Brunswick, NJ, July 13, 2017In a Star-Ledger opinion piece published on July 12, Mary Abrams, Senior Health Policy Analyst at the New Jersey Association of Mental Health and Addiction Agencies (NJAMHAA), writes:

Congress could soon weaken prescription drug coverage for more than 900,000 New Jersey residents.  Lawmakers want to fundamentally alter Medicare Part D, which has provided seniors and the disabled with affordable medicines for more than a decade.

The program has become a lifeline.  Without Part D, nearly two out of three seniors say that they would be unable to fill all of their prescriptions, while one in two say that they would be more likely to cut back or stop taking their medicines altogether. Continue reading

Seton Hall-Hackensack Meridian School of Medicine Dean Bonita Stanton Featured in ‘Industry Magazine’

Dr. Bonita Stanton

South Orange, NJ, June 21, 2017 — Dean Bonita Stanton, M.D., of the Seton Hall-Hackensack Meridian School of Medicine was interviewed and featured in the June 2017 issue of Industry Magazine.

The article, “Healthcare’s Horizon,” explores the new School of Medicine as a shift in paradigm for both medical pedagogy and health care delivery.

Noting how “The anticipated Seton Hall-Hackensack Meridian School of Medicine will offer an innovative team-based approach that will mirror how healthcare will be delivered in the future,” the article begins: Continue reading